Skye Bioscience (SKYE) enters 2025 positioned to announce Phase 2 data for nimacimab, a non-incretin mechanism and first-in-class, peripherally-restricted CB1 inhibitor antibody with the potential to enhance important facets of obesity treatment while achieving significant weight loss. Skye’s goal in 2025 is to achieve clinical milestones and new scientific insights related to the unique effects and metabolic mechanisms of peripheral CB1 inhibition. Anticipated Clinical Milestones: CBeyond Phase 2 obesity trial: completion of enrollment; CBeyond Phase 2 obesity trial: interim data targeted for Q2 2025: 50% enrollment of planned 120 patients after 26 weeks of treatment; CBeyond Phase 2 obesity trial: topline weight loss data targeted for Q4 2025 after full enrollment of 120 patients completing 26 weeks of treatment.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.